WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1997036589) USE OF 1-BENZYL-1,2,3,4-TETRAHYHYDROISOQUINOLINE FOR THE MANUFACTURE OF A MEDICAMENT FOR IMPROVING CEREBRAL FUNCTION
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/1997/036589 International Application No.: PCT/JP1997/001063
Publication Date: 09.10.1997 International Filing Date: 28.03.1997
Chapter 2 Demand Filed: 28.10.1997
IPC:
A61K 31/47 (2006.01) ,A61P 25/28 (2006.01) ,C07D 217/02 (2006.01)
Applicants: HIROBE, Masaaki[JP/JP]; JP (UsOnly)
OHTA, Shigeru[JP/JP]; JP (UsOnly)
MASUKAWA, Yoshikazu[JP/JP]; JP (UsOnly)
LEDERLE (JAPAN), LTD.[JP/JP]; 10-3, Kyobashi 1-chome Chuo-ku Tokyo 104, JP (AllExceptUS)
Inventors: HIROBE, Masaaki; JP
OHTA, Shigeru; JP
MASUKAWA, Yoshikazu; JP
Agent: KUSAMA, Osamu; Iwata Building 7th floor 5-12, Iidabashi 4-chome Chiyoda-ku Tokyo 102, JP
Priority Data:
8/9966729.03.1996JP
Title (EN) USE OF 1-BENZYL-1,2,3,4-TETRAHYHYDROISOQUINOLINE FOR THE MANUFACTURE OF A MEDICAMENT FOR IMPROVING CEREBRAL FUNCTION
(FR) UTILISATION DE 1-BENZYL-1,2,3,4-TETRAHYDROISOQUINOLEINE POUR LA FABRICATION D'UN MEDICAMENT AMELIORANT LA FONCTION CEREBRALE
Abstract:
(EN) Cerebral function improving agents containing as the active ingredient 1-benzyl-1,2,3,4-tetrahydroisoquinoline represented by formula (I) or pharmaceutically acceptable salts thereof. The compound of the above formula (I) exerts a memory disturbance improving effect and a memory retention enhancing effect through its central cholinergic effect. It causes no morphine-like dependence and has no ulcerogenic potential.
(FR) L'invention se rapporte à des agents améliorant la fonction cérébrale, agents contenant comme principe actif de la 1-benzyl-1,2,3,4-tétrahydroisoquinoléine de formule (I), ou à des sels pharmaceutiquement acceptables de cette dernière. Le composé de formule (I) atténue les troubles de la mémoire et améliore la mémorisation grâce à son effet cholinergique central. Il ne crée pas dépendance du type dépendance de la morphine et n'a pas d'effet ulcérogène.
Designated States: AU, CA, HU, IL, JP, KR, NO, US
European Patent Office (EPO) (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
Publication Language: English (EN)
Filing Language: English (EN)